Management of dyslipidaemia
Open Access
- 1 August 2004
- Vol. 90 (8) , 949-955
- https://doi.org/10.1136/hrt.2003.021287
Abstract
The simplest classification of dyslipidaemia defines the lipid phenotype as hypercholesterolaemia, hypertriglyceridaemia, or mixed hyperlipidaemia (MHL). Each can result from dysfunctional mutations of dominantly expressed genes encoding receptors, enzymes or transfer proteins involved in lipoprotein metabolism, usually indicated by a familial pattern of inheritance. More often, however, dyslipidaemia reflects the interaction between weaker genetic influences and environmental factors such as diet and a sedentary existence. In these situations the adoption of changes in lifestyle is the first line of treatment whereas monogenically determined dyslipidaemias, such as familial hypercholesterolaemia (FH), usually require lipid regulating drug treatment.Keywords
This publication has 21 references indexed in Scilit:
- Major Outcomes in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin vs Usual Care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)JAMA, 2002
- Efficacy and Safety of Statin Therapy in Children With Familial HypercholesterolemiaCirculation, 2002
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialPublished by Elsevier ,2002
- Efficacy and Safety of Ezetimibe Coadministered With Atorvastatin or Simvastatin in Patients With Homozygous Familial HypercholesterolemiaCirculation, 2002
- N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trialsThe American Journal of Medicine, 2002
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapyThe American Journal of Cardiology, 2000
- Noncholesterol Sterols and Cholesterol Lowering by Long-Term Simvastatin Treatment in Coronary PatientsArteriosclerosis, Thrombosis, and Vascular Biology, 2000
- Plant sterol and stanol margarines and healthBMJ, 2000
- Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association.1998